B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

Abstract

ObjectiveWe investigated the predictive value of the enzyme-linked immunospot technique (ELISPOT) in identifying patients with relapsing-remitting multiple sclerosis (RRMS) who will respond to treatment with glatiramer acetate (GA) or interferon-β (IFN-β), based on the brain-reactive B-cell activity of peripheral blood cells.MethodsIn this retrospective, cross-sectional, real-world multicenter study, we identified patients with RRMS in the NeuroTransData MS registry and stratified them based on their documented treatment response (relapse-free in the first 12 months of treatment) to GA or IFN-β. The GA group comprised 73 patients who responded to GA and 35 nonresponders. The IFN-β group comprised 62 responders to IFN-β and 37 nonresponders. Patients with previous or current therapy affecting B-cell activity were excluded. We polyclonally stimulated mononuclear cells from peripheral blood samples (collected after participant selection) and investigated brain-reactive B-cell activity after incubation on brain tissue lysate-coated ELISPOT plates. Validity metrics of the ELISPOT testing results were calculated (Python 3.6.8) in relation to the clinical responsiveness in the 2 treatment groups.ResultsThe ELISPOT B-cell activity assay showed a sensitivity of 0.74, a specificity of 0.76, a positive predictive value of 0.78, a negative predictive value of 0.28, and a diagnostic OR of 8.99 in predicting clinical response to GA vs IFN-β therapy in patients with RRMS.ConclusionMeasurement of brain-reactive B-cell activity by ELISPOT provides clinically meaningful predictive probabilities of individual patients' treatment response to GA or IFN-β. The assay has the potential to improve the selection of optimal first-line treatment for individual patients with RRMS.Classification of EvidenceThis study provides Class II evidence that in patients with RRMS, the brain reactivity of their peripheral-blood B cells predicts clinical response to GA and IFN-β.

Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab

“…For the quantification of the B cell response, single-color ELISPOT assays were performed according to the protocol as previously described by our group ( 32 ). Briefly, after counting the cells, PBMCs were resuspended in RPMI-1640 supplemented with 10% FBS and 1% PenStrep.…”

The prevalence of IgG antibodies against milk and milk antigens in patients with multiple sclerosis

“…For obtaining the plasma samples, approximately 35 mL of venous peripheral blood was collected in lithium-heparinized tubes and diluted 1:1 in Dulbecco’s phosphate-buffered saline (PBS). Peripheral blood mononuclear cells (PBMCs) and plasma were separated as previously described by our group ( 25 ). Briefly, PBMCs were separated from other components of the blood in Leucosep™ tubes (#227290, Greiner Bio-One) by density gradient centrifugation using Ficoll-Paque® PLUS (#17-1440-03, Cytiva).…”

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry

“…Nevertheless, the challenge in daily practice is the timely identification of the individually most effective DMT at a given time during the course of MS, particularly in patients with persistent disease activity on their current DMT, especially regarding the immanent risk of developing progressive disability or SPMS. Promising techniques emerge based on biomarker like neurofilament light chain 20 or B-cell activity response 21 or RWD-based statistical predictive algorithms. 22 As treatment decisions are driven currently by European label definitions, national cost control regulations and perceptions of physicians and patients, personaliseddata-based decision support is required to further improve individual care.…”